- Preliminary data from a Phase 1b/2a clinical trial evaluating Cotinga Pharmaceuticals' (OTCPK:COTQF +1.6%) lead candidate COTI-2, combined with the chemo agent cisplatin, in patients with p53-mutated solid tumors showed a favorable safety profile while two subjects experienced either stable cancer or regression.
- No dose-limiting toxicities have been observed to date.
- The company says COTI-2 restores the function of mutant p53, a tumor suppressor gene, inducing cancer cell death irrespective of the type of cancer. It has Orphan Drug status in the U.S. for ovarian cancer.
- Development is ongoing.